Author

D. C. B. Lye

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Organism:virus· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

B. Young· 3 shared J. G. Low· 2 shared A. Bertoletti· 1 shared A. Chia· 1 shared A. D. T. Barrett· 1 shared A. P. C. Lim· 1 shared A. T. Tan· 1 shared A. Torres· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. Young

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mutations of SARS-CoV-2 variants of concern escaping Spike-specific T cells

N. Le Bert, A. T. Tan, K. Kunasegaran, A. Chia, N. Tan, Q. Chen, S. K. Hang, M. D. Qui, B. S. Chan, J. G. Low, B. Young, K. C. Ng, D. W. S. Chan, D. C. B. Lye, A. Bertoletti

This study examines how mutations in SARS-CoV-2 variants affect Spike-specific T cell responses, finding that some mutations reduce CD8 T cell recognition while overall T cell responses remain largely intact.

bioRxiv · Jan 20, 2022 · PreprintImmunology

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody

C. E. Z. Chan, S. G. K. Seah, D. H. Chye, S. Massey, M. Torres, A. P. C. Lim, S. K. K. Wong, J. J. Y. Neo, P. S. Wong, J. H. Lim, G. S. L. Loh, D. L. Wang, J. D. Boyd-Kirkup, S. Guan, D. Thakkar, , B. J. Hanson

The paper identifies SC31, a potent SARS-CoV-2 neutralizing antibody, and shows that its Fc-mediated effector functions are critical for its therapeutic efficacy in vivo.

bioRxiv · Oct 26, 2020Microbiology

Neutralizing antibodies from early cases of SARS-CoV-2 infection offer cross-protection against the SARS-CoV-2 D614G variant.

C. Y.-P. Lee, S. N. Amrun, R. S.-L. Chee, Y. S. Goh, T. M. Mak, S. Octavia, N. Yeo, Z. W. Chang, M. Z. Tay, A. Torres, G. Carissimo, C. M. Poh, S.-W. Fong, B. Wang, S. Lee, , L. F. P. Ng

This study shows that antibodies from early SARS-CoV-2 infections neutralize both the original and D614G variants, though neutralizing capacity decreases over time.

bioRxiv · Oct 8, 2020 · PreprintImmunology